NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
Want to see IN:NATCOPHARM full AI Analyst Report?
Total Valuation
NATCO Pharma Limited has a market cap or net worth of ₹151.80B. The enterprise value is ₹157.66B.
Market Cap₹151.80B
Enterprise Value₹157.66B
Share Statistics
NATCO Pharma Limited has 179,109,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding179,109,860
Owned by Insiders―
Owned by Institutions0.06%
Financial Efficiency
NATCO Pharma Limited’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 11.34%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)11.34%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee10.16M
Profits Per Employee3.71M
Employee Count4,016
Asset Turnover0.37
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of NATCO Pharma Limited is 10.7. NATCO Pharma Limited’s PEG ratio is -0.51.
PE Ratio10.7
PS Ratio4.40
PB Ratio1.95
Price to Fair Value1.95
Price to FCF13.03
Price to Operating Cash Flow12.81
PEG Ratio-0.51
Income Statement
In the last 12 months, NATCO Pharma Limited had revenue of 40.78B and earned 14.19B in profits. Earnings per share was 79.21.
Revenue40.78B
Gross Profit33.88B
Operating Income12.30B
Pretax Income15.37B
Net Income14.19B
EBITDA17.34B
Earnings Per Share (EPS)79.21
Cash Flow
In the last 12 months, operating cash flow was 11.91B and capital expenditures -1.80B, giving a free cash flow of 10.10B billion.
Operating Cash Flow11.91B
Free Cash Flow10.10B
Free Cash Flow per Share56.40
Dividends & Yields
NATCO Pharma Limited pays an annual dividend of ₹1.5, resulting in a dividend yield of 0.57%
Dividend Per Share₹1.5
Dividend Yield0.57%
Payout Ratio5.79%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-1.84%
50-Day Moving Average1.07K
200-Day Moving Average923.19
Relative Strength Index (RSI)25.14
Average Volume (3m)59.22K
Important Dates
NATCO Pharma Limited upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
NATCO Pharma Limited as a current ratio of 3.01, with Debt / Equity ratio of 7.74%
Current Ratio3.01
Quick Ratio2.47
Debt to Market Cap0.04
Net Debt to EBITDA0.30
Interest Coverage Ratio33.51
Taxes
In the past 12 months, NATCO Pharma Limited has paid 1.19B in taxes.
Income Tax1.19B
Effective Tax Rate0.08
Enterprise Valuation
NATCO Pharma Limited EV to EBITDA ratio is 10.64, with an EV/FCF ratio of 13.40.
EV to Sales4.53
EV to EBITDA10.64
EV to Free Cash Flow13.40
EV to Operating Cash Flow10.44
Balance Sheet
NATCO Pharma Limited has ₹40.77B in cash and marketable securities with ₹2.61B in debt, giving a net cash position of ₹38.16B billion.
Cash & Marketable Securities₹40.77B
Total Debt₹2.61B
Net Cash₹38.16B
Net Cash Per Share₹213.06
Tangible Book Value Per Share₹500.55
Margins
Gross margin is 83.07%, with operating margin of 30.16%, and net profit margin of 34.78%.
Gross Margin83.07%
Operating Margin30.16%
Pretax Margin37.70%
Net Profit Margin34.78%
EBITDA Margin42.52%
EBIT Margin37.45%
Analyst Forecast
The average price target for NATCO Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-7.93%
EPS Growth Forecast-24.76%